Targeting OX40-OX40L pathway: A new era in atopic dermatitis management by T cell rebalancing. Nakajima S, Yonekura S, Kabashima K. J Allergy Clin Immunol 2025 Feb 18:S0091-6749(25)00174.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nakajima S, Yonekura S, Kabashima K. Targeting OX40-OX40L pathway: A new era in atopic dermatitis management by T cell rebalancing. J Allergy Clin Immunol 2025 Feb 18:S0091-6749(25)00174.
PMID: 39978683